Liquidia Newsroom

Liquidia Analyst Ratings

BenzingaJul 18 17:30

Needham Reiterates Buy on Liquidia, Maintains $28 Price Target

BenzingaJul 18 17:30

Buy Rating Affirmed Amid Legal Challenges and FDA Approval Prospects for Liquidia Technologies

TipRanksJul 18 04:36

Liquidia Analyst Ratings

BenzingaJul 10 19:07

HC Wainwright & Co. Reiterates Buy on Liquidia, Maintains $32 Price Target

BenzingaJul 10 19:07

Liquidia Analyst Ratings

BenzingaJun 26 01:54

Liquidia Analyst Ratings

BenzingaJun 3 19:20

Needham Reiterates Buy on Liquidia, Maintains $28 Price Target

BenzingaJun 3 19:20

Maintaining Buy Rating on Liquidia Technologies Amidst FDA Delay, Optimistic on Yutrepia's Market Potential

TipRanksMay 15 22:30

Liquidia Analyst Ratings

BenzingaMay 15 17:53

Needham Reiterates Buy on Liquidia, Maintains $28 Price Target

BenzingaMay 15 17:52

Bullish Outlook for Liquidia Technologies With Buy Rating Amid Anticipated Patent Clarity and Market Growth Opportunities

TipRanksMay 15 03:40

Analysts Offer Insights on Healthcare Companies: Intellia Therapeutics (NTLA), Liquidia Technologies (LQDA) and Pacific Biosciences (PACB)

TipRanksMay 15 01:15

Buy Rating for Liquidia Technologies: Innovation and Market Potential Drive Strong Investment Case

TipRanksApr 10 19:06

Needham: Reiterates Liquidia's (LQDA.US) rating and adjusted from buy to buy rating, target price is $28.00.

Zhitong FinanceApr 10 19:01

Liquidia Analyst Ratings

BenzingaApr 10 19:01

Analysts Offer Insights on Healthcare Companies: Rocket Pharmaceuticals (RCKT), Liquidia Technologies (LQDA) and Xtant Medical Holdings (XTNT)

TipRanksApr 2 17:15

Buy Rating Justified by Favorable Legal Outcomes and Imminent FDA Decision for Liquidia Technologies' Yutrepia

TipRanksApr 1 22:40

Liquidia Analyst Ratings

BenzingaApr 1 22:30

Needham Reiterates Buy on Liquidia, Maintains $28 Price Target

BenzingaApr 1 22:30